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Purpose of Review This paper aims to review novel trends in cholinergic neuroimaging in Alzheimer 
and Lewy body parkinsonian disorders. 
 
Recent Findings The spectrum of cholinergic imaging is expanding with the availability of spatially more 
precise radioligands that allow assessment of previously less recognized subcortical and cortical 
structures with more dense cholinergic innervation. In addition, advances in MRI techniques now 
allow quantitative structural or functional assessment of both the cholinergic forebrain and the 
pedunculopontine nucleus, which may serve as non-invasive prognostic predictors. Multimodal 
imaging approaches, such as PET-MRI or multiligand PET offer new insights into the dynamic and 
interactive roles of the cholinergic system at both local and larger-scale neural network levels.   
 
Summary Our understanding of the heterogeneous roles of the cholinergic system in age-related 
diseases is evolving. Multimodal imaging approaches that provide complimentary views of the 
cholinergic system will be necessary to shed light on the impact of cholinergic degeneration on 
regional and large-scale neural networks that underpin clinical symptom manifestation in 
neurodegeneration.  
 




Degeneration of the cholinergic system has been identified as a major component of the 
neurodegenerative dementia process in Alzheimer's disease (AD) and Lewy body parkinsonian 
disorders, including Parkinson's disease (PD) and in particular Parkinson’s disease dementia (PDD) and 
Lewy body dementia (LBD), see [1] for review. The cholinergic hypothesis of dementia is evolving from 
a primary focus on memory and a traditional view of a more diffuse neuromodulator system, toward 
more diverse cognitive and behavioural functions modulated by regionally smaller and larger scale 
neural networks [1].  
 
Prior in vivo cholinergic imaging studies in Lewy body parkinsonian disorders, for example, have shown 
both cortical and subcortical gray matter cholinergic losses that associate with postural instability and 
gait difficulties, in particular falls or freezing of gait (FOG;see [2] for review). The subcortical 
denervation differences between Alzheimer and Lewy body disorders suggest selective vulnerability 
of subcortical cholinergic cell groups between these two types of neurodegenerations [3–5], which 
may underpin the distinct cognitive changes seen in these conditions.   
 
In vivo cholinergic molecular imaging studies, such as positron emission tomography (PET) or single 
photon computed emission tomography (SPECT) imaging, allow specific assessment of the major 
cholinergic cell groups either directly (requiring higher spatial resolution imaging) or indirectly (by 
quantifying cholinergic binding in cortical or subcortical cholinergic projection target area (Table 1). 
 
-- Insert Table 1 about here. 
 
Technical advances in magnetic resonance imaging (MRI) allow quantitative assessment of the 
cholinergic basal forebrain (cBF) nuclei and more recently of the brainstem pedunculopontine nucleus 
(PPN) (Table 1). Despite relative lack of specificity due to non-cholinergic tissue components in these 
areas, clinical studies have shown sufficient sensitivity to establish robust cognitive imaging 
biomarkers in neurodegeneration [6]. 
 
The goal of this review is to identify emerging trends in recent molecular and MRI cholinergic imaging 
studies in AD and Lewy body disorders. Review findings are organized around the major themes of the 
recent literature (within the last few years).  
Cholinergic Imaging Biomarkers 
 
Cholinergic cell groups and their projections 
 
The major cholinergic nuclei are organized by numbered cell groups that have specific cholinergic 
projections to cortical and subcortical target regions [7] (Figure 1). Magnocellular neurons of the cBF 
provide the major cholinergic input to the telencephalon [7]. Ch1 (medial septal nucleus) and Ch2 
(vertical limb nucleus of the diagonal band) cholinergic neurons  provide the major input of the 
hippocampus; Ch3 (horizontal limb nucleus of the diagonal band)  cholinergic neurons project to the 
olfactory bulb; and Ch4 cholinergic neurons of the nucleus basalis of Meynert project to the remainder 
of the cerebral cortex, as well as the amygdala [8]. The Ch5 (PPN) and Ch6  (laterodorsal tegmental 
complex; LDTC) provide cholinergic input to the thalamus, several brainstem nuclei, spinal cord, 
cerebellum (via medial vestibular nucleus projections) and some striatal projections [9–11]. Intrinsic 
populations of cholinergic interneurons are also present in the striatum [12,13]. Ch5 and Ch6 striatal 
projections follow a topographic pattern where rostral PPN (Ch5) neurons preferentially innervate the 
dorsolateral striatum, and LDTC (Ch6) neurons preferentially innervate the medial striatum and 
nucleus accumbens core [14,15]. 
 




Molecular imaging biomarkers (PET and SPECT) 
 
Radioligands have been developed to label specific components of the cholinergic nerve terminal  
(table 1). Acetylcholinesterase (AChE) PET ligands were the first cholinergic imaging ligand used in 
human studies [16]. Although a synaptic enzyme, AChE has been recognized as a reliable marker for 
the integrity of cholinergic neurons [17]. Example ligands include 11C-donepezil, 11C-MP4A and 11C-
PMP. However, the presynaptic vesicular acetylcholine transporter (VAChT) is a more robust marker 
of presynaptic cholinergic integrity. Example ligands include 123I-IBVM (SPECT) and 18F-FEOBV (PET). 
Binding differences in AChE may be more difficult to interpret in neurodegeneration as lower levels 
may reflect loss of cholinergic nerve terminal integrity or possible functional downregulation due to 
regulation. In contrast, possible compensatory responses in cholinergic functions will be more 
straightforward when using VAChT ligands due to upregulation.  Another advantage of VAChT ligands 
is that these allow more accurate non-invasive quantification of cholinergic changes in high binding 
subcortical gray matter structures, such as the basal ganglia, thalamus and cerebellum [18]. There are 
also radioligands that label muscarinic (e.g., 123I-QNB M1/M4 receptor SPECT) and nicotinic receptors 
(e.g. 2-[18F]FA, 18F-flubatine PET and 123I-5IA SPECT α4β2 receptor ligands), see [2] for review. 
 
MRI imaging biomarkers 
 
Structural imaging via MRI and diffusion tensor imaging (DTI) can provide an in vivo measure of 
cholinergic system integrity. They offer complimentary information about the cholinergic system to 
PET, but are non-invasive, less expensive, and widely available.  
 
The cBF nuclei (Ch1-4) are the most well-studied with structural MRI [1,19,20]. Early in vivo cBF 
imaging with voxel based morphometry (VBM; a technique that can index brain atrophy), relied on 
mapping of a relatively gross region, defined as the ‘substantia innominata’ [21]. However, the 
availability of stereotactic cytoarchitectonic maps of the cBF in humans now permits morphometric 
assessment of the cBF at a sub-regional scale [22,23]. Maps of the cBF that allow subregional precision 
have demonstrated that degeneration is pronounced in the posterior region of the Ch4 (Ch4p) in mild 
cognitive impairment (MCI) stages of AD, progressing towards more anteriomedial cBF regions in later 
disease [22]. More recently, studies using these maps have further suggested that atrophy of the cBF 
subregions coexists with cortical atrophy corresponding to previously documented corticotopic cBF 
projections [24]. 
 
VBM is difficult within the PPN however, as this region cannot be segmented from the surrounding 
white matter in the brain stem using standard protocols [25]. Instead, researchers have used DTI to 
index the structural health of the PPN. While DTI has traditionally been used to index the structural 
integrity of white matter, it is increasingly used to assess grey matter structural changes at a 
microscopic scale [26].      
Emerging themes in the recent literature 
 
Advances in VAChT radioligands demonstrate dense cholinergic innervation in previously under-
examined regions 
 
Albin et al.[27] recently presented a detailed anatomic biodistribution assessment of 18F-FEOBV brain 
PET imaging in neurologically normal adults. In line with post-mortem human, as well as animal 
studies, binding was highest in the striatum followed by the thalamus, amygdala, hippocampus, 
vermis, cerebellar nuclei, dorsal rostral brainstem (likely associated with Ch5-Ch6), cerebellar cortex 
and neocortex. Neocortical binding was lowest in the posterior cortical regions, including the visual 
cortex. However, within the range of neocortical binding, regionally distinct and more prominent 
binding was seen in the anterior to mid cingulum, insula, and primary sensorimotor cortex.  Thalamic 
binding was also heterogeneous but with distinct uptake in the lateral geniculate nuclei. Cerebellar 
binding was highest in the vermis. Focal distinct uptake was also seen the flocculonodular lobes 
(vestibular nuclei). The patterns of cerebellar and thalamic bindings may be unique to humans [27]. 
Clinical and behavioural correlates of cholinergic bindings in these particular structures remain largely 
unexplored in the context of neurodegeneration. Therefore, VAChT PET studies may allow clinical 
correlation studies of previously less recognised structures, like the lateral geniculate nucleus and 
vestibular cerebellum.  
 
Spatial covariance studies suggest cholinergic contributions to large scale neural network changes in 
dementia 
 
Another emerging trend is the use of spatial covariance analysis of whole brain parametric cholinergic 
PET or SPECT, which suggests an important role of the cholinergic system in cognitive decline in 
neurodegeneration [28]. For example, Colloby et al.[28]  found an α4β2 nicotinic receptor spatial 
covariance pattern characterized by relative decreases in receptor binding in the cBF, PPN, limbic, 
thalamic and parietofrontal regions together with relatively preserved or increased binding in 
occipital, midbrain, cerebellar and sensorimotor cortical regions using 123I-5IA-85380 SPECT. The 
covariant pattern converged on various subcortical and neocortical regions, implicating a cholinergic 
network that mapped onto default mode network (DMN) hubs, namely, medial prefrontal, posterior 
cingulate, precuneus, and inferior parietal [29].  
 
The same authors also reported reduced M1/M4 muscarinic receptor 123I-QNB SPECT binding in basal 
forebrain, temporal, striatal, insula, and anterior cingulate regions together with concomitant 
preserved or increased binding in frontal and parieto-occipital areas in patients with PDD [30]. These 
regions overlapped with key nodes of the DMN and frontoparietal networks. 
 
We recently reported on topographic cholinergic changes in patients with LBD using VAChT PET [31]. 
Binding reductions were prominent in anterior-to-mid cingulate cortices, bilateral insula, right more 
than left lateral geniculate nuclei, bilateral anterior and superior thalami, and posterior hippocampal 
fimbria and fornices. The spatial pattern of the observed cholinergic vulnerability may involve key hubs 
of large-scale neural networks including the cingulo-opercular, visual attention, saliency and spatial 
navigation networks. These topographic changes may suggest a cholinergic vulnerability underlying 
clinical phenotypic features, such as fluctuating cognition, falls and visuospatial/visuoperceptual 
cognitive in LBD [31]. 
 
Bidirectional spatial covariance changes suggest possible cholinergic compensatory processes 
 
Spatial covariance studies of cholinergic receptors have shown evidence of topographic binding 
changes in patients with AD or LBD [28], that may reflect compensatory and/or decompensatory 
processes. In early stage disease compensatory processes may limit symptom progression [28]. A 
recent 18F-FEOBV PET study in patients with idiopathic REM sleep behaviour disorder, a common 
prodromal stage of Lewy body disorders, found significantly higher VAChT binding in specific 
brainstem areas corresponding to the bulbar reticular formation, pontine coeruleus/subcoeruleus 
complex, tegmental periacqueductal grey, and mesopontine cholinergic nuclei [32]. Furthermore, 
binding in the ventromedial area of the thalamus, deep cerebellar nuclei, and some cortical territories 
(including the paracentral lobule, anterior cingulate, and orbitofrontal cortex) was higher in the 
patients compared to controls [32]. Higher than normal range binding in these regions suggests a 
compensatory cholinergic upregulation associated with the initial phases of Lewy body 
neurodegenerations. Our voxel-based VAChT PET changes showed evidence of cholinergic 
vulnerability of key hub regions of different large scale neural networks in LBD [31]. Further research 
is needed to determine whether cholinergic changes in brain regions that spatially overlap with key 
hubs in important large-scale brain networks may result in altered compensatory or decompensatory 
functions of such networks 
 
MRI forebrain measures may expand our understanding of early pathology in AD 
 
AD is characterised by amyloid-β and tau deposition traditionally thought to originate in the entorhinal 
cortex (EC). However, recent MRI evidence now suggests that AD pathology in the cBF may occur 
earlier than in the EC. Schmitz and Spreng [33] used longitudinal VBM with cerebrospinal fluid (CSF) 
markers of amyloid-β. They demonstrated that Ch4 degeneration, but not EC degeneration, could be 
detected in cognitively healthy individuals with increased amyloid-βCSF markers, indicating prodromal 
AD. More recent evidence in two independent samples (N>800 combined) endorsed the finding that 
Ch4 atrophy proceeds and predicts EC degeneration, which in turn predicts neocortical atrophy over 
two years [34]. In addition, Cantero et al [35] demonstrated that Ch4 atrophy occurs in asymptomatic 
AD with isolated tauopathy but not isolated amyloidosis, while the extension of atrophy throughout 
the cBF depends on the presence of both proteinopathies in later AD. Together, this suggests that a 
new model of AD pathophysiology should consider the initiation of proteinopathies (especially 
tauopathy) in Ch4, which leads to cholinergic denervation in this region before cognitive symptoms 
are presented. This degeneration then extends to the EC, which is associated with neocortical atrophy 
and memory impairment. Combined proteinopathies are then associated with degeneration 
throughout the cBF in more advanced AD.  
 
A recent 18F-FEOBV VAChT PET study also reported evidence that the cBF degeneration covaries with 
longitudinal gray matter loss in the basal forebrain, cortex, and amygdala in early AD [36]. This 
covariation reflects the organization of the cBF projections [36]. The same group of authors also 
reported that 18F-FEOBV is more sensitive than either glucose metabolic or β-amyloid PET to 
distinguish AD patients from control subjects. This supports MRI evidence that cholinergic imaging 
provides novel insight into AD pathology, beyond traditional markers of amyloidosis.  
 
 
MRI offers novel non-invasive cholinergic prognostic markers in neurodegenerative conditions 
 
Recently, cBF volumetry has been extended to PD, providing the first evidence that Ch4 atrophy may 
also predict cognitive decline in this neurodegenerative disease. Barrett et al. [37] report that Ch4 
integrity is associated with impaired global cognition, attention and visuospatial function in de novo 
and more advanced PD. In a longitudinal cohort, we recently  demonstrated that baseline Ch4 volumes 
in newly diagnosed PD could predict risk of MCI over 5 years follow-up [6]. This finding was replicated 
by Schulz et al. [38], who additionally found that mean diffusivity of the Ch4 (measured with DTI) was 
a stronger predictor of future cognitive impairment in PD.  
 
More recently, Pereira et al. [39] published the first longitudinal study of conversion to PD with 
dementia (PDD) [39], in which cBF volumes were assessed over 10 years. At baseline, only those with 
current PDD or those who would later convert to PDD showed reduced Ch4 volumes compared to 
controls. Both PDD groups showed cBF atrophy beyond the Ch4, extending to Ch1/2 over time 
compared to controls and those without cognitive progression. In addition, longitudinal changes in 
Ch4 volumes significantly predicted conversion to PDD over 10 years.  
 
In AD, Jethwa et al. [40,41] found that a simple linear measurement of Ch4 thickness showed excellent 
diagnostic accuracy for differentiating controls from those with AD and late MCI  [40]. In addition, 
cognitive improvements following treatment with the acetylcholinesterase inhibitor, Donepezil, were 
found to be associated with significantly reduced annual cBF atrophy in patients with prodromal AD 
[42], implying that structural MRI measures may provide an objective marker of cholinergic treatment 
responses. Further research is required to investigate the utility of cBF volumetry as a theragnostic 
marker in neurodegenerative conditions treated with cholinergic medications. 
 
Recent evidence in non-pathological ageing [43] and vascular cognitive impairment [44] suggests that 
integrity in cBF white matter projections, but not cBF volumes, predict cognitive outcomes. White 
matter changes, which are thought to represent demyelination and axonal damage, may be witnessed 
earlier than grey matter atrophy measured with volumetry [45]. As such, longitudinal multimodal 
approaches, which include DTI-based metrics, are necessary to improve our understanding of the 
spatiotemporal patterns of neurodegeneration.  
 
Recent VAChT PET and PPN MRI studies provide novel insights into cholinergic system changes 
underlying postural instability and gait difficulties in PD  
 
Postural instability and gait difficulties (PIGD), in particular falls and freezing of gait (FOG), are among 
the most disabling motor features in PD and generally have little response to dopaminergic therapy in 
advancing disease [46]. Additionally, PIGD symptoms are associated with poorer cognitive outcomes 
and rapid development of PDD [47]. We previously associated PPN/LTDC-thalamic and cBF 
corticopetal cholinergic projection system degeneration with falls and slow gait speed in PD, 
respectively [48,49].  These studies were performed using AChE PET, which limits accurate 
quantification of high binding subcortical areas.  
 
Recently, we reported on 18F-FEOBV VAChT regional binding changes in PD patients with falls and FOG 
[50]. We were able to confirm our previous observation of reduced PPN/LTDC-thalamic binding in 
fallers compared to non-fallers. A novel observation was that there was more prominent reduction of 
binding in the lateral geniculate nucleus, caudate nucleus (both more abnormal in the right 
hemisphere) and bilateral prefrontal cortices. In the same study, freezers had lower VAChT binding in 
the bilateral striatum, limbic archicortices and temporal and mesiofrontal limbic regions compared to 
non-freezers. These observations suggest different cholinergic systems changes underpin falls and 
FOG in PD.  
 
In line with these PET findings, previous MRI research demonstrated that reduced connectivity 
between the PPN and cerebellum [51] and prefrontal regions [52] is associated with freezing of gait in 
PD.  A striking finding from the latter paper was that degeneration of the right PPN in particular was 
associated with FOG.  
 
Recently, Alho et al [53] developed a stereotactic map of the bilateral PPN to facilitate targeting of 
this nucleus for deep brain stimulation. Using this map along with DTI in a longitudinal cohort, we  
found that diffusivity in the PPN, but not Ch4, predicted future PIGD symptoms in PD [54]. This 
relationship was independent from the relationship between caudate dopamine deficiency and future 
PIGD, suggesting dopaminergic and cholinergic contributions to PIGD are distinct. Importantly, these 
data imply that microstructural changes in the PPN could be used to predict future PIGD symptoms.  
 
Taken together, right hemispheric predominance of VAChT system in fallers and PPN changes 
associated with future PIGD motor features in PD could support a selective right hemispheric 
vulnerability. This is consistent with a growing body of literature suggesting that right-hemisphere 
circuitry seems to be particularly implicated in these symptoms [55–57]. The ventral attention 
network, which responds to unexpected stimuli and is highly integrated with the visual system, 
lateralizes to the non-dominant hemisphere [58]. This may suggest that deficiency of saliency 
detection may be a mechanism underlying fall risk in PD. Vulnerability of the right lateral geniculate 
nucleus may possibly reflect a prior observation of a subtle left hemi-neglect consisting of a directional 
(right hemi-field) bias of initial visual exploration in PD [59]. Alternatively, there is also evidence of 
right hemispheric dominance of vestibular cortical functions [60]. This may suggest vestibular 
dysfunction as a contributing factor to fall risk in PD. In this respect and in view of the predominant 
right PPN MRI findings, cholinergic losses in Ch5 may result in impaired integrity of the medial 
vestibular nucleus which is the major source of cholinergic cerebellar innervation, including the 
vestibulocerebellum [11]. 
 
Multimodal approaches provide further insight into the spatiotemporal patterns of cholinergic 
degeneration and its role in cognitive decline 
 
Considering the many overlapping themes from molecular and MRI cholinergic imaging studies, it is 
unsurprising that there is a growing trend for research to employ multimodal imaging techniques, 
which can provide a more holistic view of subcortical and cortical, as well as structural and functional, 
cholinergic integrity.  For example, research combining MRI and PET [61] found that cBF atrophy in 
MCI correlated specifically with memory and attentional deficits, and these dissociated deficits were 
mediated by hypometabolism in specific cortical regions. Similar evidence of dissociated cognitive 
changes were reported in research combining diffusion-based tractography and resting state 
functional MRI in non-demented PD [26]. Reduced structural and functional connectivity between 
Ch3/4(Ch4) and associative frontal, occipital, peri-insular areas and medial/pulvinar thalamus were 
associated with deficits in global cognition and fronto-executive functions. On the other hand, reduced 
functional connectivity between Ch1/2 and the medial temporal lobe was associated with memory 
deficits [26]. This supports the PD literature that suggests that Ch4 degeneration is associated with 
global cognition and attention deficits [6,37,38], whereas in PDD [39] and AD [22,33,34] degeneration 





The spatial brain regional detail of cholinergic imaging has vastly improved in recent years through the 
increasing use of VAChT PET and detailed MRI cytoarchitectonic maps of the cBF, both of which enable 
examination of small structures with dense cholinergic innervation. Recent VAChT PET studies show 
regionally distinct and more prominent cholinergic binding in cortical and subcortical gray matter 
structures, such as the lateral geniculate nucleus, vestibular cerebellum and the primary sensorimotor 
cortex. cBF volumetric MRI has shown utility as a non-invasive prognostic marker in AD and 
parkinsonian Lewy body disorders. Both techniques show promise to further clinical phenotyping 
studies to elucidate specific roles in the neurodegenerative process. 
 
In addition to advances in regional imaging, whole brain PET/SPECT imaging or combined PET-MRI 
imaging suggests cholinergic contributions to large scale neural network changes. Multimodal 
approaches suggest that cBF atrophy may proceed symptom presentation and cognitive deficits are 
associated with cortical atrophy corresponding to corticotopic cBF projections. Furthermore, recent 
advances in PPN MRI and whole brain VAChT PET suggest that a cholinergic vulnerability in regional 
neural system changes may also underlie dopaminergic-resistant gait and balance impairment in PD. 
Taken together, these findings endorse the recent revival and evolution of the cholinergic hypothesis 
of dementia [1,20,62]. AD and PD may lie on a cholinergic spectrum, whereby PD without cognitive 
complaint show spared cBF nuclei but reduced midpontine cholinergic integrity, whereas Lewy body 
parkinsonian disorders, including LBD and PDD, show both cBF and midpontine degeneration, 
associated with their motor and cognitive symptoms [20]. 
 
Future multimodal PET-MRI imaging approaches will help elucidate the spatiotemporal gradient of 
cholinergic degeneration across different neurodegenerative diseases and possible large or regional 
scale network hub roles of cholinergic structures. Inclusion of DTI metrics may identify whether white 
matter microstructural changes precede the documented GM atrophy in the cBF, aiding earlier 
prognosis. Early prognostic biomarkers would allow potentially disease-modifying interventions to be 
applied before more debilitating symptoms develop.   
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Table and figure legends 
 
Table 1. Major cholinergic imaging biomarkers and functions. Abbreviations: AChE, 
acetylcholinesterase; DTI, diffusion tensor imaging; PPN: pedunculopontine nucleus; VAChT: 
Vesicular Acetylcholine Transporter 
 
Figure 1. The Human Cholinergic System. Cholinergic nuclei are primarily located in numbered cell 
groups in the basal forebrain (cBF [in red]; including Ch1-4) and brainstem (Ch5/PPN, Ch6/LDT [in 
blue]). Ch1/2 mainly project to the hippocampus; Ch3 projects to the olfactory bulb and Ch4 has 
projections throughout the cerebral cortex and to the amygdala. Ch5 (PPN) and Ch6 (LDT) have 
cholinergic projections to the thalamus, brainstem, spinal cord, cerebellum and striatum. Recent 
advances in VAChT radioligands demonstrate dense cholinergic innervation in previously under-
examined cortical and subcortical regions, including the lateral geniculate nucleus (LGN), vestibular 
cerebellum and primary sensorimotor cortex (PSC). The lower pons medial vestibular nucleus (MVN 
[in yellow]) provides the major cholinergic input to the cerebellar vestibular nuclei. Ch5 likely 
provides cholinergic input to the MVN. Other intrinsic populations of cholinergic neurons include 
interneurons in the striatum [in purple]. 
